CPCameron Pinkelton

Cameron Pinkelton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cameron Pinkelton has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating the Impact of VOICE (Values and Outcomes to Improve Cancer Experiences), a Values-Clarification Tool, among Older Adults with Advanced Cancer: A Randomized Study in Simulated Clinical Settings

    by Amy C. Cole, Angela M. Stover, Andy J. King, Allison M. Deal, Cameron Pinkelton, Michael Johnson, Lisa Vizer, Fei Yu, Lukasz Mazur, Daniel R. Richardson

    Background: Patients often report that clinical guidance does not reflect personal values, such as balancing survival with quality of life. Values-clarification tools can improve treatment alignment but have been understudied. Objective: To evaluate the impact of the Values and Outcomes to Improve Cancer Experiences (VOICE) tool on values clarification and shared decision making (SDM) in simulated encounters. Methods: Adults (age ≥60 y) with advanced cancer were randomized to receive VOICE or an American Cancer Society (ACS) communication guide. Participants completed 2 simulated decision-making encounters in randomized order, values based (VB; clinician-initiated discussion of patient values) and non–values based (NVB; values addressed only if patient initiates), with medical students. Two independent raters assessed values‑clarification and SDM behaviors (interrater reliability = 0.82). Patient-reported SDM was assessed with validated measures. Postsimulation interviews were thematically analyzed. Results: Forty-four adults (aged 60–88 y) participated in 88 simulated encounters focused on discussing a secondary cancer diagnosis and treatment options. VOICE recipients demonstrated higher rater-assessed values clarification than those receiving the ACS guide in VB (91.5 vs 80.1, P = 0.01) and NVB (25.2 vs 16.2, P = 0.01) encounters. During NVB encounters, more participants receiving VOICE initiated a values discussion (48% vs 13%). Values-clarification ratings were higher when clinicians initiated VB discussions than patient-initiated discussions (92.9 vs 35.7; P < 0.001). Patient-reported SDM was better in VB versus NVB encounters (relative risk [RR] = 1.71, P = 0.04). VOICE better prepared participants for SDM (70.0 vs 0.0; P < 0.001). Qualitative findings suggest VOICE led to greater self-reflection and values clarification. Conclusions: In this randomized simulation study, VOICE improved older adults’ preparation for values-based discussions and supported reflection on how treatment options align with what matters most to them. Findings highlight the importance of pairing values-clarification tools with clinician-initiated values-based discussions and for further evaluation in real-world settings.

  • Open Access

    Evaluating The Effects of Clinician Prescribing and Implementation Materials on Adoption of Virtual Reality Therapeutics: A Randomized Feasibility Pilot Study (Preprint)

    by Ashlyn Zebrowski, Jackson Fernandez, Cameron Pinkelton, Rebecca Kitzmiller, Adam Kiefer, Laura Stanley, Gita Mody, Carlton Moore, Lukasz Mazur

    Virtual reality therapeutics (VRx) are emerging as a form of digital therapeutics (DTx) with growing evidence for improving symptoms such as anxiety, pain, and distress. However, real-world adoption remains limited because successful use depends not only on the therapeutic benefits but also on how the intervention is introduced, supported, and integrated into care, in addition to the therapeutic benefits. Existing literature has identified barriers related to clinician familiarity, prescribing pathways, onboarding, and independent use outside the clinic, but few studies have experimentally evaluated how implementation strategies influence early adoption outcomes. This feasibility pilot study evaluated how different implementation strategies influence early adoption of a VRx intervention in a nonclinical setting by comparing unguided VRx use, self-directed VRx use with implementation materials, and VRx use with prescriber-led consultation and support. An institutional review board–approved, 3-arm randomized feasibility pilot study was conducted following the Virtual Reality Clinical Outcomes Research Experts framework and reported using the CONSORT (Consolidated Standards of Reporting Trials) 2010 extension guidelines for pilot and feasibility studies. Participants were randomly allocated to 1 of 3 experimental conditions. Outcomes included technology acceptance, usability, fidelity, and tolerability. Quantitative measures were complemented by qualitative exit interviews. Analyses were exploratory, and the study was not powered for hypothesis testing. Across conditions, brief VRx exposure was associated with significant improvements in overall technology acceptance (P<.001), though postintervention scores remained in the neutral range, indicating early shifts rather than strong endorsement. Participants receiving provider-supported implementation demonstrated the most consistent pattern of favorable outcomes, including higher fidelity of use and significantly greater time-based adherence (P=.04). Usability scores were generally favorable across conditions. Tolerability was acceptable, with low levels of reported cybersickness and no discontinuations due to adverse effects. Qualitative findings highlighted the importance of guidance, expectation-setting, and perceived clinical legitimacy in shaping engagement. This study demonstrates that implementation strategy is a key determinant of adoption for virtual reality–based DTx. By experimentally isolating onboarding and provider support components, this work extends prior efficacy-focused research to address implementation design. Findings suggest that brief provider involvement and structured onboarding may enhance engagement and adherence, supporting future evaluation of scalable DTx implementation models in clinical and community settings.

  • Open Access

    Evaluating The Effects of Clinician Prescribing and Implementation Materials on Adoption of Virtual Reality Therapeutics: A Randomized Pilot Study (Preprint)

    by Ashlyn Zebrowski, Jackson Fernandez, Cameron Pinkelton, Rebecca Kitzmiller, Adam Kiefer, Laura Stanley, Gita Mody, Carlton Moore, Lukasz Mazur

    BACKGROUND Digital therapeutics (DTx) are emerging as effective, evidence-based interventions for mental health conditions, serving as both complements to and alternatives to traditional treatments. Virtual reality (VR) has demonstrated particular promise as a delivery modality, leveraging immersion and engagement to enhance user experience and improve clinical outcomes. Despite growing evidence supporting VR-based digital therapeutics, little is known about the implementation strategies required to support widespread adoption by patients and clinicians. In particular, the fit of VR therapeutics within clinical workflows, including prescribing, onboarding, and delivery outside the clinic, remains insufficiently explored. OBJECTIVE This pilot randomized study evaluated how implementation materials and provider engagement impact acceptability, usability, and fidelity of VRx use in the non-clinical setting. Three experimental conditions were evaluated: (1) unguided VRx use, (2) self-directed VRx with assistive training materials, and (3) clinician-prescribed VRx with assistive training materials. METHODS Healthy adults (N=31) were randomized into three conditions: (1) VRx exposure without support, (2) VRx with self-directed training and assistive materials, or (3) VRx with provider-led instruction and prescription. A mixed-methods approach grounded in human factors was applied. Technology acceptance (TAM), usability (SUS), and engagement were assessed pre- and post-intervention. Observational methods captured user interaction patterns, including task completion rates, error frequency, help-seeking behaviors, and adaptation strategies. Qualitative feedback further contextualized usability challenges, perceived workload, and the role of support systems in shaping user confidence and adoption. RESULTS All groups showed significant increases in acceptance post-intervention (p<.001). Condition 3 demonstrated the strongest improvements across all acceptability measures and the highest engagement, with participants spending 99% of prescribed time in VRx. Provider interaction reinforced perceived safety, increased adherence, and enhanced willingness to adopt VRx. In contrast, training materials alone produced modest improvements, suggesting limited effectiveness without human guidance. CONCLUSIONS This is the first study to experimentally compare different implementation strategies for VRx adoption. Findings highlight the pivotal role of clinician involvement in improving acceptance, usability, and engagement. Structured instructional support and provider endorsement may be essential for scaling VRx and digital therapeutics in real-world care.